Related references
Note: Only part of the references are listed.Joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards on recommended use of [18F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.0
E. Lopci et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2022)
Artificial intelligence and radiomics: fundamentals, applications, and challenges in immunotherapy
Laurent Dercle et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)
Patterns of progression in patients treated for immuno-oncology antibodies combination
Alice Bernard-Tessier et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)
Intratumoral Immunotherapy: From Trial Design to Clinical Practice
Stephane Champiat et al.
CLINICAL CANCER RESEARCH (2021)
Comparing RECIST 1.1 and iRECIST in advanced melanoma patients treated with pembrolizumab in a phase II clinical trial
Firas S. Ahmed et al.
EUROPEAN RADIOLOGY (2021)
Spleen glucose metabolism on [18F]-FDG PET/CT: a dynamic double-edged biomarker predicting outcome in cancer patients
Romain-David Seban et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2021)
Reassessing Patterns of Response to Immunotherapy with PET: From Morphology to Metabolism
Larissa B. Costa et al.
RADIOGRAPHICS (2021)
Spleen Glucose Metabolism on [18F]-FDG PET/CT for Cancer Drug Dis-covery and Development cannot be Overlooked
Romain-David Seban et al.
CURRENT CANCER DRUG TARGETS (2021)
Toward Generalizability in the Deployment of Artificial Intelligence in Radiology: Role of Computation Stress Testing to Overcome Underspecification
Thomas Eche et al.
RADIOLOGY-ARTIFICIAL INTELLIGENCE (2021)
Immune-related Adverse Events and Survival in Solid Tumors Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
Fausto Petrelli et al.
JOURNAL OF IMMUNOTHERAPY (2020)
First-in-Humans Imaging with 89Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion Targeting
Neeta Pandit-Taskar et al.
JOURNAL OF NUCLEAR MEDICINE (2020)
Early 18F-FDG PET/CT Response Predicts Survival in Relapsed or Refractory Hodgkin Lymphoma Treated with Nivolumab
Aiping Chen et al.
JOURNAL OF NUCLEAR MEDICINE (2020)
The immune-metabolic-prognostic index and clinical outcomes in patients with non-small cell lung carcinoma under checkpoint inhibitors
Angelo Castello et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2020)
Diagnosis of Hyperprogressive Disease in Patients Treated with Checkpoint Inhibitors Using 18F-FDG PET/CT
Romain-David Seban et al.
JOURNAL OF NUCLEAR MEDICINE (2020)
Dissociated responses at initial computed tomography evaluation is a good prognostic factor in non-small cell lung cancer patients treated with anti-programmed cell death-1/ligand 1 inhibitors
Takehiro Tozuka et al.
BMC CANCER (2020)
Identification of Non-Small Cell Lung Cancer Sensitive to Systemic Cancer Therapies Using Radiomics
Laurent Dercle et al.
CLINICAL CANCER RESEARCH (2020)
Prognostic 18F-FDG PET biomarkers in metastatic mucosal and cutaneous melanoma treated with immune checkpoint inhibitors targeting PD-1 and CTLA-4
Romain-David Seban et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2020)
FDG PET/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment
Amir Iravani et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2020)
Diagnosis of Hyperprogressive Disease in Patients Treated with Checkpoint Inhibitors Using 18F-FDG PET/CT Reply
Angelo Castello et al.
JOURNAL OF NUCLEAR MEDICINE (2020)
Immune-Related Adverse Events (irAEs): Diagnosis, Management, and Clinical Pearls
Eli P. Darnell et al.
CURRENT ONCOLOGY REPORTS (2020)
Cachexia - sarcopenia as a determinant of disease control rate and survival in non-small lung cancer patients receiving immune-checkpoint inhibitors
Benoit Roch et al.
LUNG CANCER (2020)
Immune-related adverse events of checkpoint inhibitors
Manuel Ramos-Casals et al.
NATURE REVIEWS DISEASE PRIMERS (2020)
18F-FDG Pet Parameters and Radiomics Features Analysis in Advanced Nsclc Treated with Immunotherapy as Predictors of Therapy Response and Survival
Giulia Polverari et al.
CANCERS (2020)
Sarcopenia and high NLR are associated with the development of hyperprogressive disease after second-line pembrolizumab in patients with non-small-cell lung cancer
M. P. Petrova et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2020)
Clarification of Definitions of Hyperprogressive Disease During Immunotherapy for Non-Small Cell Lung Cancer
Baptiste Kas et al.
JAMA ONCOLOGY (2020)
Predicting response to immunotherapy in advanced non-small-cell lung cancer using tumor mutational burden radiomic biomarker
Bingxi He et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Response Criteria for Intratumoral Immunotherapy in Solid Tumors: itRECIST
Gregory V. Goldmacher et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Performance of CT Compared with 18F-FDG PET in Predicting the Efficacy of Nivolumab in Relapsed of Refractory Hodgkin Lymphoma
Fatima-Zohra Mokrane et al.
RADIOLOGY (2020)
Dissociated Response in Metastatic Cancer: An Atypical Pattern Brought Into the Spotlight With Immunotherapy
Olivier Humbert et al.
FRONTIERS IN ONCOLOGY (2020)
Radiomics to predict outcomes and abscopal response of patients with cancer treated with immunotherapy combined with radiotherapy using a validated signature of CD8 cells
Roger Sun et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade
Giuseppe Lo Russo et al.
CLINICAL CANCER RESEARCH (2019)
Sub-cutaneous Fat Mass measured on multislice computed tomography of pretreatment PET/CT is a prognostic factor of stage IV non-small cell lung cancer treated by nivolumab
Geoffrey Popinat et al.
ONCOIMMUNOLOGY (2019)
Predicting Response to Immunotherapy by Evaluating Tumors, Lymphoid Cell-Rich Organs, and Immune-Related Adverse Events Using FDG-PET/CT
Tomomi Nobashi et al.
CLINICAL NUCLEAR MEDICINE (2019)
Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics
Romain-David Seban et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2019)
Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma
Nicholas D. Klemen et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Machine learning defined diagnostic criteria for differentiating pituitary metastasis from autoimmune hypophysitis in patients undergoing immune checkpoint blockade therapy
Ahmed Mekki et al.
EUROPEAN JOURNAL OF CANCER (2019)
Imaging-guided precision medicine in glioblastoma patients treated with immune checkpoint modulators: research trend and future directions in the field of imaging biomarkers and artificial intelligence
Mathieu Sinigaglia et al.
EJNMMI RESEARCH (2019)
Novel patterns of response under immunotherapy
E. Borcoman et al.
ANNALS OF ONCOLOGY (2019)
Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
Satya Das et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Imaging of Cancer Immunotherapy: Current Approaches and Future Directions
Mizuki Nishino et al.
RADIOLOGY (2019)
F-18-FDG PET and CT Scans Detect New Imaging Patterns of Response and Progression in Patients with Hodgkin Lymphoma Treated by Anti-Programmed Death 1 Immune Checkpoint Inhibitor
Laurent Dercle et al.
JOURNAL OF NUCLEAR MEDICINE (2018)
Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1
Ahmed Mekki et al.
EUROPEAN JOURNAL OF CANCER (2018)
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis
Shrujal Baxi et al.
BMJ-BRITISH MEDICAL JOURNAL (2018)
Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis
Shrujal Baxi et al.
BMJ-BRITISH MEDICAL JOURNAL (2018)
Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer
Laura Mezquita et al.
JAMA ONCOLOGY (2018)
Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small Cell Lung Cancer
Koji Haratani et al.
JAMA ONCOLOGY (2018)
A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study
Roger Sun et al.
LANCET ONCOLOGY (2018)
Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy
Roberto Ferrara et al.
JAMA ONCOLOGY (2018)
Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT)
A. Marabelle et al.
ANNALS OF ONCOLOGY (2018)
Zr-89-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer
Frederike Bensch et al.
NATURE MEDICINE (2018)
18F-FDG PET/CT Can Predict Development of Thyroiditis Due to Immunotherapy for Lung Cancer
Naghmehossadat Eshghi et al.
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY (2018)
Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1
Stephane Champiat et al.
CLINICAL CANCER RESEARCH (2017)
Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: A multi-institutional retrospective study
Yasuhiro Nakamura et al.
JOURNAL OF DERMATOLOGY (2017)
Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials
Dirk Schadendorf et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
Lesley Seymour et al.
LANCET ONCOLOGY (2017)
Monitoring immune-checkpoint blockade: response evaluation and biomarker development
Mizuki Nishino et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Immune-mediated Disease in Ipilimumab Immunotherapy of Melanoma with FDG PET-CT
Jason W. Wachsmann et al.
ACADEMIC RADIOLOGY (2017)
Immune-Related Tumor Response Dynamics in Melanoma Patients Treated with Pembrolizumab: Identifying Markers for Clinical Outcome and Treatment Decisions
Mizuki Nishino et al.
CLINICAL CANCER RESEARCH (2017)
Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate
Shumei Kato et al.
CLINICAL CANCER RESEARCH (2017)
irRECIST and iRECIST: the devil is in the details
J. Le Lay et al.
ANNALS OF ONCOLOGY (2017)
Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
E. Saada-Bouzid et al.
ANNALS OF ONCOLOGY (2017)
Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy
Bruce D. Cheson et al.
BLOOD (2016)
Abscopal effect in a Hodgkin lymphoma patient treated by an anti-programmed death 1 antibody
Jean-Marie Michot et al.
EUROPEAN JOURNAL OF CANCER (2016)
Rapid and objective CT scan prognostic scoring identifies metastatic patients with long-term clinical benefit on anti-PD-1/-L1 therapy
Laurent Dercle et al.
EUROPEAN JOURNAL OF CANCER (2016)
Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab
F. Stephen Hodi et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Molecular Imaging of Immunotherapy Targets in Cancer
Emily B. Ehlerding et al.
JOURNAL OF NUCLEAR MEDICINE (2016)
Pseudoprogression and Immune-Related Response in Solid Tumors
Victoria L. Chiou et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Immunotherapy response assessment in neuro-oncology: a report of the RANO working group
Hideho Okada et al.
LANCET ONCOLOGY (2015)
Cancer Immunotherapy: Imaging Assessment of Novel Treatment Response Patterns and Immunerelated Adverse Events
Jennifer J. Kwak et al.
RADIOGRAPHICS (2015)
When Progressive Disease Does Not Mean Treatment Failure: Reconsidering the Criteria for Progression
Geoffrey R. Oxnard et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
Synthesis of 2′-Deoxy-2′-[18F]Fluoro-9-β-D-Arabinofuranosylguanine: a Novel Agent for Imaging T-Cell Activation with PET
Mohammad Namavari et al.
MOLECULAR IMAGING AND BIOLOGY (2011)
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
Jedd D. Wolchok et al.
CLINICAL CANCER RESEARCH (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Clinical significance of diffusely increased 18F-FDG uptake in the thyroid gland
Dimitrios Karantanis et al.
JOURNAL OF NUCLEAR MEDICINE (2007)
Share Paper
